Transmembrane interactions are needed for KAI1/CD82-mediated suppression of cancer invasion and metastasis

American Journal of Pathology

Volumn 174, Issue 2, 2009, Pages 647-660

  Bari, Rafijul ^a   Zhang, Yanhui H ^a   Zhang, Feng ^a   Wang, Nick X ^b   Stipp, Christopher S ^c   Zheng, Jie J ^b   Zhang, Xin A ^a,d  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c UNIVERSITY OF IOWA   (United States)

^d Vascular Biology Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD151 ANTIGEN; CD82 ANTIGEN; CD9 ANTIGEN; TETRASPANIN; UNCLASSIFIED DRUG; VERY LATE ACTIVATION ANTIGEN 3;

ARTICLE; CANCER INVASION; CELL INTERACTION; CELL MIGRATION; CONTROLLED STUDY; DIMERIZATION; FIBROSARCOMA; HUMAN; HUMAN CELL; METASTASIS; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DENATURATION; PROTEIN DOMAIN; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN GLYCOSYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; PROTEIN STRUCTURE;

EID: 59649129853     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.2353/ajpath.2009.080685     Document Type: Article

References (54)

1. Jackson P, Marreiros A, Russell PJ: KAI1 tetraspanin and metastasis suppressor. Int J Biochem Cell Biol 2005, 37:530-534
2. Tonoli H, Barrett JC: CD82 metastasis suppressor gene: a potential target for new therapeutics? Trends Mol Med 2005, 11:563-570
3. Liu WM, Zhang XA: KAI1/CD82, a tumor metastasis suppressor. Cancer Letter 2006, 240:183-194
4. Dong J-T, Lamb PW, Rinker-Schaeffer CW, Vukanovic J, Ichikawa T, Issacs JT, Barrett JC: KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2. Science 1995, 268:884-886
5. Ono M, Handa K, Withers DA, Hakomori S: Motility inhibition and apoptosis are induced by metastasis-suppressing gene product CD82 and its analogue CD9, with concurrent glycosylation. Cancer Res 1999, 59:2335-2339
6. Schoenfeld N, Bauer MKA, Grimm S: The metastasis suppressor gene C33/CD82/KAI1 induces apoptosis through reactive oxygen intermediates. FASEB J 2003, 18:158-160
7. Bandyopadhyay S, Zhan R, Chaudhuri A, Watabe M, Pai SK, Hirota S, Hosobe S, Tsukada T, Miura K, Takano Y, Saito K, Pauza ME, Hayashi S, Wang Y, Mohinta S, Mashimo T, Iiizumi M, Furuta E, Watabe K: Interaction of KAI1 on tumor cells with DARC on vascular endothelium leads to metastasis suppression. Nat Med 2006, 12:933-938
8. Boucheix C, Rubinstein E. Tetraspanins. Cell Mol Life Sci 2001, 58:1189-1205
9. Hemler ME: Tetraspanin functions and associated microdomains. Nat Rev Mol Cell Biol 2005, 6:801-811
10. Imai T, Fukudome K, Takagi S, Nagira M, Furuse M, Fukuhara N, Nishimura M, Hinuma Y, Yoshie O: C33 antigen recognized by monoclonal antibodies inhibitory to human T cell leukemia virus type 1-induced syncytium formation is a member of a new family of transmembrane proteins including CD9, CD37, CD53, and CD63. J Immunol 1992, 149:2879-2886
11. Gil ML, Vita N, Lebel-Binay S, Miloux B, Chalon P, Kaghad M, Marchiol-Fournigault C, Conjeaud H, Caput D, Ferrara P: A member of the tetra spans transmembrane protein superfamily is recognized by a monoclonal antibody raised against an HLA class I-deficient, lymphokine-activated killer-susceptible, B lymphocyte line. cloning and preliminary functional studies. J Immunol 1992, 148:2826-2833
12. Nojima Y, Hirose T, Tachibana K, Tanaka T, Shi L, Doshen J, Freeman GJ, Schlossman SF, Morimoto C: The 4F9 antigen is a member of the tetra spans transmembrane protein family and functions as an accessory molecule in T cell activation and adhesion. Cell Immunol 1993, 152:249-260
13. Kovalenko OV, Metcalf DG, DeGrado WF, and Hemler ME: Structural organization and interactions of transmembrane domains in tetraspanin proteins. BMC Struct Biol 2005, 5:11
14. Seigneuret M: Complete predicted three-dimensional structure of the facilitator transmembrane proteins and hepatitis C virus receptor CD81: conserved and variable structural domains in the tetraspanin family. Biophysical J 2006, 90:212-227
15. Tu L, Kong XP, Sun TT, Kreibich G: Integrity of all four transmembrane domains of the tetraspanin uroplakin Ib is required for its exit from the ER. J Cell Sci 2006, 119:5077-5086
16. Gratkowski H, Lear JD, DeGrado WF: Polar side chains drive the association of model transmembrane peptides. Proc Natl Acad Sci USA 2001, 98:880-885
17. Zhou FX, Merianos HJ, Brunger AT, Engelman DM: Polar residues drive association of polyleucine transmembrane helices. Proc Natl Acad Sci USA 2001, 98:2250-2255
18. Call ME, Pyrdol J, Wiedmann M, Wucherpfennig KW: The organizing principle in the formation of the T cell receptor-CD3 complex. Cell 2002, 111:967-979
19. Call ME, Schnell JR, Xu C, Lutz RA, Chou JJ, Wucherpfennig KW: The structure of the zetazeta transmembrane dimer reveals features essential for its assembly with the T cell receptor. Cell 2006, 127:355-368
20. Cosson P, Lankford SP, Bonifacino JS, Klausner RD: Membrane protein association by potential intramembrane charge pairs. Nature 1991, 351:414-416
21. Blumberg RS, Alarcon J, Sancho J, McDermott FV, Lopez P, Breitmeyer J, Terhorst C: Assembly and function of the T cell antigen receptor. Requirement of either the lysine or arginine residues in the transmembrane region of the alpha chain. J Biol Chem 1990, 265:14036-14043
22. Alocover A, Mariuzza RA, Ermonval M, Acuto O: Lysine 271 in the transmembrane domain of the T-cell antigen receptor beta chain is necessary for its assembly with the CD3 complex but not for alpha/beta dimerization. J Biol Chem 1990, 265:4131-4135
23. Fuller-Espie S, Hoffman Towler P, Wiest DL, Tietjen I, Spain LM: Transmembrane polar residues of TCR beta chain are required for signal transduction. Int Immunol 1998, 10:923-933
24. Fukudome K, Furuse M, Imai T, Nishimura M, Takagi S, Hinuma Y, Yoshie O: Identification of membrane antigen C33 recognized monoclonal antibodies inhibitory to HTLV-1 induced syncytium formation: altered glycosylation of C33 antigen in HTLV-1-positive cells. J Virol 1992, 66:1394-1401
25. Charrin S, Le Naour F, Oualid M, Billard M, Faure G, Hanash SM, Boucheix C, Rubinstein E: The major CD9 and CD81 molecular partner. Identification and characterization of the complexes. J Biol Chem 2001, 276:14329-14337
26. White MM, Foust JT, Mauer AM, Robertson JT, Jennings LK: Assessment of lumiaggregometry for research and clinical laboratories. Thromb Haemost 1992, 67:572-577
27. Yauch RL, Berditchevski F, Harler MB, Reichner J, Hemler ME: Highly stoichiometric, stable and specific association of integrin α3β1 with CD151 provides a major link to PI 4-kinase and may regulate cell migration. Mol Biol Cell 1998, 9:2751-2765
28. Nishiuchi R, Sanzen N, Nada S, Sumida Y, Wada Y, Okada M, Takagi J, Hasegawa H, Sekiguchi K: Potentiation of the ligand-binding activity of integrin α3β1 via association with CD151. Proc Natl Acad Sci USA 2005, 102:1939-1944
29. Hemler ME, Sanchez-Madrid F, Flotte TJ, Krensky AM, Burakoff SJ, Bhan AK, Springer TA, Strominger JL: J Immunol 1984, 132:3011-3018
30. Zhang XA, Bontrager AL, Stipp CS, Kraeft SK, Bazzoni G, Chen LB, Hemler ME: Phosphorylation of a conserved integrin alpha 3 QPSXXE motif regulates signaling, motility, and cytoskeletal engagement. Mol Biol Cell 2001, 12:351-365
31. Zhou B, Liu L, Reddivari M, Zhang XA: The palmitoylation of metastasis suppressor KAI1/CD82 is important for its motility-inhibitory activity. Cancer Res 2004, 64:7455-7463
32. CAS-Crk coupling in KAI1/CD82-mediated suppression of cell migration. J Biol Chem 2003, 278:27319-27328
33. Kovalenko OV, Yang X, Kolesnikova TV, Hemler ME: Evidence for specific tetraspanin homodimers: inhibition of palmitoylation makes cysteine residues available for cross-linking. Biochem J 2004, 377:407-417
34. Fuse C, Ishida Y, Hikita T, Asai T, Oku N: Junctional adhesion molecule-C promotes metastatic potential of HT1080 human fibrosarcoma. J Biol Chem 2007, 282:8276-8283
35. Schweinitz A, Steinmetzer T, Banke IJ, Arlt MJ, Stürzebecher A, Schuster O, Geissler A, Giersiefen H, Zeslawska E, Jacob U, Krüger A, Stürzebecher J: Design of novel and selective inhibitors of urokinase-type plasminogen activator with improved pharmacokinetic properties for use as antimetastatic agents. J Biol Chem 2004, 279:33613-33622
36. Winterwood NE, Varzavand A, Meland MN, Ashman LK, Stipp CS: A critical role for tetraspanin CD151 in {alpha}3{beta}1 and {alpha}6{beta}4 integrin-dependent tumor cell functions on laminin-5. Mol Biol Cell 2006, 2707-2721
37. Schwede T, Kopp J, Guex N, Peitsch MC: SWISS-MODEL: an automated protein homology-modeling server. Nucleic Acids Research 2003, 31:3381-3385
38. Cornell WD, Cieplak P, Bayly CI, Gould IR, Merz KM, Jr., Ferguson DM, Spellmeyer DC, Fox T, Caldwell JW, Kollman PA: A second generation force field for the simulation of proteins, nucleic acids and organic molecules. J Am Chem Soc 1995, 117:5179-5197
39. Onufriev A, Bashford D, Case DA: Modification of the generalized born model suitable for macromolecules. J Phys Chem B 2000, 104:3712-3720
40. Iwata S, Kobayashi H, Miyake-Nishijima R, Sasaki T, Souta-Kuribara A, Nori M, Hosono O, Kawasaki H, Tanaka H, Morimoto C: Distinctive signaling pathways through CD82 and beta1 integrins in human T cells. Eur J Immunol 2002, 32:1328-1337
41. Takaoka A, Hinoda Y, Sato S, Itoh F, Adachi M, Hareyama M, Imai K: Reduced invasive and metastatic potentials of KAI1-transfected melanoma cells. Jpn J Cancer Res 1998, 89:397-404
42. Yang X, Wei LL, Tang C, Slack R, Mueller S, Lippman ME: Overexpression of KAI1 suppresses in vitro invasiveness and in vivo metastasis in breast cancer cells. Cancer Res 2001, 61:5284-5288
43. Yang XH, Kovalenko OV, Kolesnikova TV, Andzelm MM, Rubinstein E, Strominger JL, Hemler ME: Contrasting effects of EWI proteins, integrins, and protein palmitoylation on cell surface CD9 organization. J Biol Chem 2006, 281:12976-12985
44. Longhurst CM, Jacobs JD, White MM, Crossno JT Jr., Fitzgerald DA, Bao J, Fitzgerald TJ, Raghow R, Jennings LK: Chinese hamster ovary cell motility to fibronectin is modulated by the second extracellular loop of CD9. Identification of a putative fibronectin binding site. J Biol Chem 2002, 277:32445-32452
45. Sugiura T, Berditchevski F: Function of alpha3 beta1-tetraspanin protein complexes in tumor cell invasion. Evidence for the role of the complexes in production of matrix metalloproteinase 2 (MMP-2). J Cell Biol 1999, 146:1375-1389
46. Zhang XA, Lane WS, Charrin S, Rubinstein E, Liu L: EWI2/PGRL Associates with the metastasis suppressor KAI1/CD82 and inhibits the migration of prostate cancer cells. Cancer Res 2003, 63:2665-2674
47. Curran AR, DM Engelman: Sequence motifs, polar interactions and conformational changes in helical membrane proteins. Curr Opin Struc Biol 2003, 13:412-417
48. Charrin S, Rubinstein E: A physical and functional link between cholesterol and tetraspanins. Eur J Immunol 2003, 33:2479-2489
49. Todeschini AR, Dos Santos JN, Handa K, Hakomori SI: Ganglioside GM2/tetraspanin CD82 complex inhibits Met activation, and its crosstalk with integrins: basis for control of cell motility through glycosynapse. J Biol Chem 2007, 282:8123-8133
50. Goldberg AF, Moritz OL, RS Molday: Heterologous expression of photoreceptor peripherin/rds and Rom-1 in COS-1 cells: assembly, interactions, and localization of multisubunit complexes. Biochemistry 1995, 34:14213-14219
51. Wu XR, Medina JJ, Sun TT: Selective interactions of UPIa and UPIb, two members of transmembrane 4 superfamily, with distinct single transmembrane-domained proteins in differentiated urothelial cells. J Biol Chem 1995, 270:29752-29759
52. Min G, Wang H, Sun TT, Kong XP: Structural basis for tetraspanin functions as revealed by the cryo-EM structure of uroplakin complexes at 6-A resolution. J Cell Biol 2006, 173:975-983
53. Bienstock RJ, Barrett JC: KAI1, a prostate metastasis suppressor: prediction of solvated structure and interactions with binding partners; integrins, cadherins, and cell-surface receptor proteins. Mol Carcinog 2001, 32:139-153
54. Cannon KS, Cresswell P: Quality control of transmembrane domain assembly in the tetraspanin CD82. EMBO J 2001, 20:2443-2453